PSA: The Pharmaceutical Strategy Conference,
September 28-30, 2015 at the Marriott Marquis in New York City, is the only meeting over the past 25 years to gather the industry’s top thinkers to explain solutions to the fundamental challenges facing pharmaceutical and biotech companies. PSA offers case studies from senior level executives such as CEOs, Business Development Executives, and Heads of R&D. Not only will they share lessons learned and practical advice for finalizing a deal, but these key opinion leaders will also debate issues on enhancing R&D productivity, approaches to market access, opportunities and risks with digital health technologies, and doing more with less in business development.
Register Today! Take advantage of the discounted registration offer and
receive $200 per person off registration rates! Don't forget to use the Priority Code: NewYorkBio.
Listen to these influential biopharma leaders:
- Everett Neville, RPh, Senior Vice President, Supply Chain, Express Scripts
- Philip Blake, President, Bayer Corporation
- Michael Hayden, President of Global R&D & CSO, Teva Pharmaceuticals
- Francis Cuss, MB, BChir, FRCP, Executive Vice President, R&D and Chief Scientific Officer, Bristol-Myers Squibb
- George Yancopoulos, MD, Chief Scientific Officer, Regeneron Pharmaceuticals
- C. David Nicholson, Executive Vice President, Global Brands R&D, Actavis
- Jim Burns, Head of R&D, Sanofi-Genzyme
- Iain Dukes, SVP Business Development & Licensing, Merck Research Laboratories
- Sophie Kornowski-Bonnet, Global Head of Roche Partnering, Roche
- Uwe Schoenbeck, PhD, Chief Scientific Officer, External R&D Innovation (ERDI), Senior Vice President, Worldwide R&D, Pfizer
- David Donabedian, VP & Head Ventures and Early Stage Collaborations, AbbVie Inc.
- Kumar Srinivasan, VP, Scientific Partnering and Alliances, AstraZeneca
- Ellen Lubman, VP, Head, External Science & Innovation, Allergan
- Paola Casarosa, PhD, Corporate VP, Head of BD&L/ Prescription Medicines, Boehringer Ingelheim GmbH
- Tariq Kassum, MD, Vice President, Business Development and Strategy, Millennium: The Takeda Oncology Company
- Philippe Drouet, President, Hospira
- Deborah Dunsire, President & CEO, Forum Pharmaceuticals
- Jane Osbourn, Ph.D., SVP and Head, Biosuperiors, MedImmune (a division of AstraZeneca)
- Andre Turenne, Managing Director, Genzyme Australia and New Zealand
- Sophie Opdyke, VP, Commercial Development, Biosimilars, Global Established Pharma BU, Pfizer
- David Shaywitz, MD, PhD, CMO, DNAnexus
- Oleg Nodelman, Founder and Managing Director, EcoR1 Capital
- Peter Kolchinsky, PhD, Managing Director, RA Capital Management, LLC
- Simos Simeonidis, PhD, MBA, Managing Director/Senior Biotech Analyst, RBC Capital Markets
- Roger Longman, CEO, Real Endpoints
- Dave Stevenson, Managing Director, Merck’s Global Health Innovation Fund
- David Kreutter, VP, Business Analytics and Insights, Pfizer
- Jeffrey D. Marrazzo, Co-Founder & CEO, Spark Therapeutics
- Sam Rasty, PhD, VP & Head of New Products, Rare Diseases Business Unit, Shire
- Garrett Ingram, VP, Head of US Market Access, Sanofi
- Michael Williams, COO, Intarcia
- Leena Das-Young, Pharm.D., VP, Late Phase Strategy, Development, Submission, & Lifecycle Management Group, Pfizer Oncology
- Lauren Sabella, CCO, Acorda Therapeutics
- Bernhardt G. Zeiher, MD, FACP, FCCP, President, Global Development, Astellas
Full List of Speakers | PSA 2015 Agenda Now Available for Download
|
